Company intelligence / Profile preview

ELG

Somerset, New Jersey, United Stateselglaw.com ↗

Ownership: Private
Development stage: Other

Overview

Legend Biotech’s lead product, ciltacabtagene autoleucel ("CARVYKTI"), is an FDA-approved BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma. Five-year survival data presented at ASCO in June 2025 demonstrated groundbreaking results. The company continues to expand its pipeline with new oncologic and hematologic therapies using advanced cellular engineering platforms.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCAR-NK cell therapyCAR-gamma delta T cell therapyNon-gene-editing CAR technologiesNanobody-based drugs
Industry: Biotech

Partnerships

Janssen Biotech Inc. (Johnson & Johnson subsidiary)—co-development of ciltacabtagene autoleucel/CARVYKTI®

Beyond the preview

Go deeper on ELG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELG.

Explore the full profile